Nutriband Chairman to Present at NobleCon21, Highlighting Abuse-Deterrent Transdermal Technology

Nutriband Inc. Chairman and Co-Founder Serguei Melnik will present at NobleCon21, Noble Capital Markets' annual emerging growth equity conference on December 3. The presentation offers investors insight into the company's development of transdermal pharmaceutical products, particularly its lead product: an abuse-deterrent fentanyl patch incorporating proprietary AVERSA technology. This technology is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, addressing a critical public health concern as opioid abuse remains prevalent in the United States and globally.

The AVERSA technology can be incorporated into any transdermal patch, providing broad application potential across multiple pharmaceutical products that carry abuse risks. Investors and conference guests may attend at a discounted rate using code NTRBNOBLECON, while a high-definition webcast will be available the following day at https://nobleconference.com and https://Channelchek.com, where it will remain archived for 90 days. The full press release detailing the announcement can be viewed at https://nnw.fm/Bx5x3.

Emerging growth equity conferences like NobleCon21 serve as important venues for companies to communicate their value proposition and growth potential directly to potential investors and financial analysts. For Nutriband, this presentation represents an opportunity to showcase its technology platform and business strategy to the investment community. The company's focus on transdermal pharmaceutical products positions it within a specialized segment of the pharmaceutical industry where innovation in drug delivery systems can significantly impact patient safety and public health outcomes.

Investors following Nutriband can access the latest news and updates relating to NTRB in the company's newsroom at https://nnw.fm/NTRB. The company maintains its corporate website at https://www.nutriband.com, though the company notes that any material contained in or derived from its websites is not part of the official press release. The presentation's timing coincides with ongoing efforts to combat opioid abuse, making Nutriband's technology particularly relevant as healthcare systems seek solutions to prevent prescription drug misuse while maintaining effective pain management options for patients.